Daunorubicin/cytarabine
(Redirected from Vyxeos liposomal)
 Cytarabine | |
 Daunorubicin | |
| Combination of | |
|---|---|
| Daunorubicin | Anthracycline |
| Cytarabine | Antimetabolite |
| Clinical data | |
| Trade names | Vyxeos |
| Other names | CPX-351 |
| AHFS/Drugs.com | Monograph |
| License data | |
| Pregnancy category |
|
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Daunorubicin/cytarabine, sold under the brand name Vyxeos, is a fixed-dose combination medication used for the treatment of acute myeloid leukemia.[4][6] It contains the liposomal bound daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, a nucleoside metabolic inhibitor.[4]
Medical uses
[edit]Daunorubicin/cytarabine is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in people aged one year of age and older.[4][7][8][9][10]
References
[edit]- ^ a b "Vyxeos APMDS". Therapeutic Goods Administration (TGA). 15 June 2022. Archived from the original on 18 June 2022. Retrieved 18 June 2022.
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
- ^ "Health product highlights 2021: Annexes of products approved in 2021". Health Canada. 3 August 2022. Retrieved 25 March 2024.
- ^ a b c d "Vyxeos (- daunorubicin and cytarabine liposome injection, powder, lyophilized, for suspension". DailyMed. 13 April 2021. Archived from the original on 29 March 2021. Retrieved 18 June 2022.
- ^ "Vyxeos liposomal EPAR". European Medicines Agency (EMA). 23 August 2018. Retrieved 25 May 2024.
- ^ Molica M, Perrone S, Mazzone C, Cesini L, Canichella M, de Fabritiis P (June 2022). "CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML". Cancers. 14 (12): 2843. doi:10.3390/cancers14122843. PMC 9221356. PMID 35740508.
- ^ "Vyxeos (cytarabine/daunorubicin liposomal) dosing, indications, interactions, adverse effects, and more". Medscape. Archived from the original on 15 August 2017. Retrieved 19 March 2019.
- ^ "Vyxeos (cytarabine and daunorubicin) FDA Approval History". Drugs.com. Archived from the original on 11 April 2019. Retrieved 30 December 2018.
- ^ Chen EC, Fathi AT, Brunner AM (2018). "Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML". OncoTargets and Therapy. 11: 3425–3434. doi:10.2147/OTT.S141212. PMC 6003284. PMID 29928134.
- ^ Cafaro A, Giannini MB, Silimbani P, Cangini D, Masini C, Ghelli Luserna Di Rorà A, et al. (October 2020). "CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia". Minerva Medica. 111 (5): 455–466. doi:10.23736/S0026-4806.20.07017-2. PMID 32955826. S2CID 221842680.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |